NCT02564614View on ClinicalTrials.gov

A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult Participants With Hepatocellular Carcinoma (HCC)

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

May 2, 2016

Primary Completion Date

January 22, 2018

Study Completion Date

January 22, 2018

Conditions
Carcinoma, Hepatocellular
Interventions
DRUG

RO7070179

RO7070179 (13 mg/kg/week) will be administered as 2-hour IV infusion.

Trial Locations (7)

10016

Laura and ISAAC Perlmutter Cancer Center at NYU Langone., New York

NYU Langone Medical Center; Bellevue Hospital, New York

10021

Weill Cornell Medical College, New York

10032

Columbia University Medical Center, New York

43210

Ohio State University, Columbus

44718

Gabrail Cancer Center, Canton

46202

Indiana University, Indianapolis

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02564614 - A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult Participants With Hepatocellular Carcinoma (HCC) | Biotech Hunter | Biotech Hunter